Skip to main content
. Author manuscript; available in PMC: 2022 Jan 12.
Published in final edited form as: Circulation. 2020 Oct 27;143(2):145–159. doi: 10.1161/CIRCULATIONAHA.120.049813

Figure 5. 12,13-diHOME improves cardiac function and respiration via NOS1 and RyR.

Figure 5.

(A) Systolic and (B) diastolic function in wild-type (WT) (n=6) or NOS1−/− mice (n=6). (C) Peak shortening, (D) Ca2+ transient, (E) maximal velocity of shortening, and (F) maximal velocity of relengthening in isolated cardiomyocytes from NOS1−/− mice treated with PBS or 12,13-diHOME. Data are mean ± S.E.M (n=5/group; 5-16 myocytes per mouse). (G) Bioenergetic profile of NOS1−/− cardiomyocytes treated with 12,13-diHOME or vehicle. (H) Basal OCR, (I) maximal respiration, and (J) non-mitochondrial respiration were measured. Data are mean ± S.E.M (n=5/group). (K) Bioenergetic profile of cardiomyocytes treated with 12,13-diHOME or vehicle with or without tetracaine. (L) Basal OCR, (M) maximal respiration, and (N) non-mitochondrial respiration were measured. Data are mean ± S.E.M (n=5/group). Asterisks represent differences compared to vehicle (*P<0.05; ***P<0.001), compared to vehicle + tetracaine (#P<0.05; ###P<0.001), or compared to 12,13-diHOME + tetracaine ($$$P<0.001). (O) Proposed model for 12,13-diHOME to regulate cardiac function via NOS1. Unpaired two-tailed Student’s t-test was used for A, B, C, D, E, F, H, I, and J. Two-way ANOVA was used for G and K with Tukey’s multiple comparisons tests. One-way ANOVA was used for L, M, and N with Tukey’s multiple comparisons tests.